"Shortage and Cost Concerns: Newborn RSV Shot in High Demand"

The recent approval of the RSV monoclonal antibody Nirsevimab has raised hopes for protecting infants from RSV, a leading cause of hospitalization and death among babies. However, the limited supply and high cost of Nirsevimab, along with bureaucratic obstacles in Medicaid's vaccine distribution system, have hindered its availability. Demand for the antibody has already outstripped supply, prompting the CDC to issue interim guidance on prioritizing high-risk infants. Additionally, the rollout of the RSV vaccine from Pfizer has faced challenges due to concerns about potential preterm births. The lack of clarity on where and when newborns should receive the shot has left many parents confused. Health systems are hoping to keep infants out of the hospital this winter, as last year's RSV surge overwhelmed hospitals and prompted public health emergencies.